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Background: Increasing age has been recognized as a cause for adverse prognosis in
the setting of myocardial infarction, coronary angioplasty, and cardiac surgery. This
is attributed to a greater susceptibility of the senescent heart to ischemic injury and
to a lower response to protective interventions. This study investigated the effect of
aging on the tolerance to ischemia of the human myocardium and its response to
ischemic preconditioning.
Methods: Right atrial specimens from 128 patients undergoing elective heart sur-
gery were collected, sliced, and equilibrated for 30 minutes before being random-
ized into 3 study protocols: (1) 210 minutes of aerobic incubation (time-matched
control), (2) 90 minutes of simulated ischemia and 120 minutes of reoxygenation,
and (3) ischemic preconditioning with 5 minutes of ischemia and 5 minutes of
reoxygenation before 90 minutes of ischemia and 120 minutes of reoxygenation.
Patients were subdivided into 3 age groups: 30 to 49 years, 50 to 69 years, and 70
to 90 years. At the end of each protocol, tissue injury and viability were assessed by
the leakage of creatine kinase and the reduction of 3-(4,5 dimethylthiazol-2-yl)-2,5
diphenyltetrazolium bromide to insoluble formazan dye.
Results: There were no differences among the 3 groups of patients in their comorbid
conditions or their cardiac medications. Ischemic injury was similar in all 3 groups
(creatine kinase 4.1 0.7, 3.6 1.0, and 4.3 1.1 U/g wet weight, respectively;
3-(4,5 dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide  64.7  31.3, 96.3
 32.0, and 61.0  30.4 mM/g wet weight, respectively, P  not significant in all
cases), and ischemic preconditioning equally protected against ischemia at all ages
(creatine kinase 1.9 0.5, 1.8 0.4, and 2.1 0.6 U/g wet weight, respectively;
3-(4,5 dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide  157.9  31.5,
170.7 35.3, and 138.4 43.8 mM/g wet weight, respectively; P .05 in all cases
vs ischemia alone).
Conclusion: Age does not influence the tolerance of the human myocardium to
ischemia or the protective effect of ischemic preconditioning. These results indicate
the need for a reevaluation of the importance of age in risk scoring in cardiac
surgery.
Increasing age has been recognized as a cause for adverse prognosis inmyocardial infarction,1,2 coronary angioplasty,3 and cardiac surgery.4,5 Thisthesis is supported by animal6 and human7 in vitro studies suggesting thatthe aged myocardium is more susceptible to ischemic injury than is theyoung myocardium. However, Ivanov and colleagues5 recently reported animprovement in operative mortality during heart surgery in the past 2
decades despite an increase in the prevalence of elderly patients and the greater
severity of their risk factors, which indicates that the associated comorbid condi-
tions, not age per se, are the main detrimental factors. The undefined role of age as
a risk factor during cardiac surgery is also reflected by the differences in the risk
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scoring systems of Parsonnet8 and the European System for
Cardiac Operative Risk Evaluation (EuroSCORE).9
It is also unclear whether the protection obtained with
interventions such as ischemic preconditioning is altered in
the aging heart. Ischemic preconditioning with brief periods
of ischemia has been demonstrated to protect both ani-
mal10,11 and human12,13 myocardium from a subsequent
ischemic insult. This has been demonstrated in aged rabbit14
and sheep15 hearts, but it has been questioned in the aged
myocardium of rat heart.16,17
This study determines the effect of age on the tolerance
of the human myocardium to ischemia and investigates
whether age affects the protection afforded by ischemic
preconditioning.
Methods
Experimental Preparation
Experiments were performed on myocardium obtained from the
right atrial appendage of 128 patients undergoing elective coronary
artery surgery or aortic valve replacement in an in vitro model that
was developed in our laboratory and described previously.18 Pa-
tients were excluded if they had enlarged atriums, atrial arrhyth-
mias, poor left ventricular function (ejection fractions  30%),
right ventricular failure, or diabetes mellitus or were taking oral
hypoglycemic agents, opioid analgesia, KATP channel openers, or
catecholamines. All other medications were discontinued 1 day
before surgery. Local ethical committee approval was obtained for
the harvesting technique. The specimens were collected in oxy-
genated HEPES buffered solution at 4°C to 5°C and immediately
sectioned and prepared for study. Briefly, the appendage was
mounted onto a ground glass plate with the epicardial surface face
down and then sliced freehand with use of surgical skin graft
blades (Swann-Morton, Sheffield, UK) to a thickness of between
300 and 500 m. The muscles (weight 30-50 mg) were then
transferred to conical flasks (25 mL Erlenmeyer flasks Schott
Glaswerk, Mainz, Germany) containing 10 mL of oxygenated
buffered solution, and the flasks were placed in a shaking water
bath maintained at 37°C. The oxygenation of the incubation me-
dium was maintained by a continuous flow of 95% O2/5% CO2 gas
mixture to obtain a PO2 between 185 and 225 mm Hg and a PCO2
between 45 and 50 mm Hg. The PO2, PCO2, and pH in the
incubation medium were monitored by intermittent analyses of the
effluent by using an automated blood gas analyzer (model 855
Blood Gas System, Chiron Diagnostics, Halstead, United King-
dom), and the pH was kept between 7.36 and 7.45. For the
induction of simulated ischemia, the medium was bubbled with
95% N2/5% CO2 (pH 6.80-7.00) and D-glucose replaced with
2-deoxyglucose. The incubation media was bubbled with 95%
N2/5% CO2 for 20 minutes before the induction of simulated
ischemia or ischemic preconditioning. Previous studies in our
laboratory have demonstrated that the O2 was 0 Kpa within 2
minutes of the initiation of bubbling. The atrial tissue was not
paced, and the force developed was not measured in these studies.
Solutions
The incubation medium was prepared daily with deionized dis-
tilled water and contained (in millimoles per liter) NaCl2 (118),
KCl (4.8), NaHCO3 (27.2), MgCl2 (1.2), KH2PO4 (1.0), CaCl2
(1.25), D-glucose (10), and HEPES (20). As mentioned previously,
D-glucose was substituted with 2-deoxyglucose (10 mmol/L) dur-
ing simulated ischemia to maintain a constant osmolarity.
Experimental Protocol
After the atrium was sectioned, the preparations were allowed to
stabilize for 30 minutes and then randomly allocated to one of the
following groups: (1) aerobic perfusion for 210 minutes, to serve
as aerobic time-matched controls, (2) simulated ischemia for a
period of 90 minutes followed by 120 minutes of reoxygenation,
and (3) ischemic preconditioning induced by 5 minutes of isch-
emia and 5 minutes of reoxygenation immediately before the 90
minutes of ischemia—a protocol shown to afford maximal protec-
tion in this preparation.19 Patients were divided into 3 different
groups according to age (30-49 years [n  18], 50-69 years [n 
66], and 70-90 years [n  44]) to allow comparison between the
different age groups.
Assessment of Tissue Injury and Viability
Tissue injury was determined by measuring the leakage of creatine
kinase (CK) into the incubation medium during the 120-minute
reoxygenation period. This was assayed by a kinetic ultraviolet
method based on the formation of nicotinamide adenine dinucle-
otide (No. 1340-K, Sigma, St Louis, Mo), and the results were
expressed as units per gram wet weight.
Tissue viability was assessed by the reduction of 3-(4,5
dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT)
to a blue formazan product at the end of the experimental time.
The tissue was loaded into a Falcon conical tube (15 mL,
Becton Dickinson Labware, Franklin Lakes, NJ) into which 2
mL of phosphate buffer solution (0.05 mol/L), containing MTT
(1.25 mg/mL, 3 mmol/L at final concentration), was added and
then incubated for 30 minutes at 37°C. After this, the tissue was
homogenized in 2 mL of dimethyl sulfoxide (Homogenizer
Ultra-Turrax T25, dispersing tool G8, IKA-Labortechnic,
Staufen, Germany) at 9500 rpm for 1 minute. The homogenate
was then centrifuged at 1000g for 10 minutes, and 0.2 mL of the
supernatant was dispensed into a 98-well flat-bottom microtiter
plate (Nunc Brand Products, Roskilde, Denmark). After this,
the absorbance of the blue formazan formed was measured on
a plate reader (Benchmark, Bio-Rad Laboratories, Hercules,
Calif) at 550 nm, and the results were expressed as millimoles
per gram wet weight.
Statistical Analysis
All data are presented as mean  standard deviation. Analysis of
variance was used for multiple comparisons with the application of
the Tukey post hoc test. Linear regression analysis was used when
appropriate.
Results
The demographic data, the risk factors, and the medical
treatment were similar in the 3 age groups (see Table 1).
Figure 1 shows that simulated ischemia and reoxygen-
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ation resulted in significant increases in CK leakage and
decreases in MTT reduction that were similar in all 3 age
groups. They also show that ischemic preconditioning
afforded similar protection in all age groups. Linear
regression analyses clearly demonstrated that the degree
of ischemic injury and the protection obtained with isch-
emic preconditioning does not change with increasing
age (R2  0.0051, 104, and 0.0178 for CK leakage and
R2  0.0216, 4  105, and 0.0295 for MTT reduction
for aerobic control, simulated ischemia, and reoxygen-
Figure 1. Creatine kinase (CK) leakage into the media (a) during the 120-minute reoxygenation period and 3-(4,5
dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT) reduction by the slices (b) at the end of the reoxy-
genation period in the human atrial myocardium from the different age groups subjected to 90 minutes of simulated
ischemia and 120 minutes of reoxygenation preceded or not by ischemic preconditioning. Data are expressed as
mean  standard deviation of the patients in each group (30-49 years of age [n  18], 50-69 years of age [n  66],
and 70-90 years of age [n  44]; *P < .05 versus aerobic control group; †P < .05 versus simulated ischemia and
reoxygenation alone group).
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ation alone, and ischemic preconditioning in all patients,
respectively).
Discussion
This study is the first to report that the necrosis induced by
a severe ischemic insult of human atrial myocardium is not
exacerbated by increasing age, and that ischemic precondi-
tioning equally protects the myocardium of all ages as
assessed by CK leakage and MTT reduction. These findings
have important clinical implications regarding the selection
and treatment of patients presenting with ischemic syn-
dromes and warrant further discussion.
Ischemia occurs in a number of clinical settings that
include myocardial infarction, coronary angioplasty, and
cardiac surgery. Ischemic heart syndromes are the most
common cause of death in elderly patients,1,2 and it has been
suggested that a greater vulnerability to ischemic injury of
this age group is a major contributor.1-4 This thesis finds
support in experimental studies showing that a greater cal-
cium overload20 and increased oxygen free-radical genera-
tion21 occur in the senescent rat heart and that hearts be-
come less tolerant to ischemia with age.6 However, the
results from this study show that the degree of ischemic
injury in the human myocardium does not seem to be related
to age. The controversy is further fueled by the results
recently reported by Mariani and colleagues7 showing that
aged human atrial myocardium (also obtained from patients
undergoing cardiac surgery) has a reduced capacity to re-
cover developed force after hypoxia or simulated ischemia
than younger myocardium, although contraction duration,
time to peak tension, and time to 50% relaxation were
unaffected by age. Therefore, the results of the study by
Mariani and colleagues7 may be subject to different inter-
pretations depending on the parameter examined. In trying
to reconcile these results, it is possible that preconditioning
by ischemia can take many forms, and that some protection
may be lost with age, whereas other forms are retained.
Indeed, the confirmation of this hypothesis requires further
investigation.
Ischemic injury as measured by the 2 parameters used in
our study was unaffected by age. Thus, the use of age as a
risk factor in mortality and morbidity after myocardial in-
farction,1,2 in patients undergoing coronary angioplasty,3 or
during cardiac surgery4,5 may be questionable. This may
indicate that the greater incidence of comorbidities in el-
derly patients is more important for risk stratification than
age per se. Therefore, in light of the present results, thera-
peutic interventions such as cardiac surgery should not be
decided on the basis of age alone, and they prompt us to
reevaluate the impact of age in the risk scoring systems of
Parsonnet8 and EuroSCORE.9
The second major finding of the present study is that the
protection of the human atrial myocardium by ischemic
preconditioning against ischemic necrosis is not influenced
by age. This contrasts with the findings of Abete and col-
leagues17 showing that the senescent rat heart cannot be
preconditioned with ischemia. However, despite these re-
sults, these investigators also showed that both adult and
senescent hearts can be equally pharmacologically precon-
ditioned with exogenous norepinephrine, indicating that the
preconditioning signal transduction pathway is preserved in
both age groups. This is further supported by reports from
McCully and colleagues14 and Burns and colleagues15 dem-
onstrating the ability to precondition the senescent hearts of
rabbits and sheep. The mechanism of ischemic and phar-
macologic preconditioning is the object of intense investi-
gation and not fully understood; however, Tani and col-
leagues16 observed differences in the translocation of
protein kinase C between young and middle-aged rats that
demonstrates the possibility of distinct characteristics in the
signaling pathway of preconditioning in different age
groups. The elucidation of this pathway will be invaluable
to exploit the protective action of preconditioning and to
combat ischemic injury. The use and refinement of precon-
ditioning will help to improve the prognosis and outcome of
the sufferers of ischemic heart disease in the elderly popu-
lation and will make procedures such as coronary angio-
plasty and cardiac surgery safer.
A potential limitation of the present study is that the
investigation was performed using human atrial tissue in-
stead of ventricular myocardium; therefore, any extrapola-
tion to the latter should be performed with caution.
Speechly-Dick, Grover, and Yellon, however, have sug-
gested that preconditioning exerts identical protection in
both tissues.12 Another possible limitation is that we used an
in vitro model, and extrapolation of this to the clinical
setting should also be performed with caution. Finally, it
should be clarified that the results obtained in the present
study may not be extended to other degrees of tissue injury
TABLE 1. Patients’ demographic data and medical treat-
ment
Group 1
(30-49 yr)
Group 2
(50-69 yr)
Group 3
(70-90 yr)
Number of patients 18 66 44
Sex (male:female) 12:6 39:27 28:16
Hypertension 8 (44%) 31 (46%) 22 (52%)
Hypercholesterolemia 12 (66%) 39 (59%) 28 (63%)
Cerebrovascular accident 1 (5%) 4 (6%) 5 (11%)
Peripheral vascular disease 1 (5%) 8 (12%) 6 (14%)
Medications
Nitrates 14 (78%) 50 (76%) 35 (80%)
Diuretics 6 (33%) 21 (32%) 15 (34%)
Ca channel antagonists 13 (72%) 41 (62%) 25 (56%)
-blockers 12 (66%) 39 (59%) 21 (48%)
ACE inhibitors 11 (61%) 31 (47%) 20 (45%)
ACE, Angiotensin-converting enzyme.
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and to the effect on contractile function or electrophysi-
ologic properties of the tissue.
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